The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph− acute lymphoblastic leukemia cells

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

Minucci, S., & Pelicci, P. G. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1779 · Cited by 2,211 · see citing works

Acute Lymphoblastic Leukemia

Pui, C., & Evans, W. E. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390907 · Cited by 841 · see citing works

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

Fielding, A. K., Richards, S. M., Chopra, R., Lazarus, H. M., Litzow, M. R., Buck, G. A. N., Durrant, I. J., Luger, S. M., Marks, D. I., FRANKLIN, I. M., et al. (2006) · Blood · doi:10.1182/blood-2006-05-018192 · Cited by 841 · see citing works

CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTS

Drummond, D. C., Noble, C. O., Kirpotin, D. B., Guo, Z., Scott, G. K., & Benz, C. C. (2004) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095825 · Cited by 598 · see citing works

Gene expression changes associated with progression and response in chronic myeloid leukemia

Radich, J. P., Dai, H., Mao, M., Oehler, V., Schelter, J., Druker, B., Sawyers, C., Shah, N., Stock, W., Willman, C. L., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510423103 · Cited by 583 · see citing works

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications

Mitsiades, C. S., Mitsiades, N., McMullan, C. J., Poulaki, V., Shringarpure, R., Hideshima, T., Akiyama, M., Chauhan, D., Munshi, N. C., Gu, X., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536759100 · Cited by 532 · see citing works

Prospects: Histone deacetylase inhibitors

Dokmanovic, M., & Marks, P. A. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20532 · Cited by 480 · see citing works

Histone deacetylase inhibitors in cancer therapy

Johnstone, R. W., & Licht, J. D. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00165-x · Cited by 448 · see citing works

Regulation of histone deacetylase activities

Sengupta, N., & Seto, E. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20179 · Cited by 347 · see citing works

GADD45b and GADD45g are cdc2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress

Vairapandi, M., Balliet, A. G., Hoffman‐Liebermann, B., & Liebermann, D. A. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10140 · Cited by 343 · see citing works

Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

Catley, L. P., Weisberg, E., Kiziltepe, T., Tai, Y., Hideshima, T., Neri, P., Tassone, P., Atadja, P. W., Chauhan, D., Munshi, N. C., et al. (2006) · Blood · doi:10.1182/blood-2006-04-016055 · Cited by 335 · see citing works

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3

George, P., Bali, P., Annavarapu, S., Scuto, A., Fiskus, W. C., Guo, F., Sigua, C. A., Sondarva, G. V., Moscinski, L. C., Atadja, P. W., et al. (2004) · Blood · doi:10.1182/blood-2004-09-3413 · Cited by 327 · see citing works

A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies

Giles, F. J., Fischer, T. H., Cortes, J. E., Garcia‐Manero, G., Beck, J., Ravandi, F., Masson, E., Rae, P., Laird, G., Sharma, S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0511 · Cited by 312 · see citing works

Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability

Caron, C., Boyault, C., & Khochbin, S. (2005) · BioEssays · doi:10.1002/bies.20210 · Cited by 292 · see citing works

The Histone Deacetylase Inhibitor LBH589 Is a Potent Antimyeloma Agent that Overcomes Drug Resistance

Maiso, P., Carvajal‐Vergara, X., Ocio, E. M., López‐Pérez, R., Mateo, G., Gutierrez, N. C., Atadja, P. W., Pandiella, A., & Miguel, J. F. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4186 · Cited by 237 · see citing works

Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review

Acharya, M. R., Sparreboom, A., Venitz, J., & Figg, W. D. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.014167 · Cited by 231 · see citing works

Dasatinib: A tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome—positive acute lymphoblastic leukemia

Steinberg, M. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.11.005 · Cited by 219 · see citing works

The Stress-Responsive Gene GADD45G Is a Functional Tumor Suppressor, with Its Response to Environmental Stresses Frequently Disrupted Epigenetically in Multiple Tumors

Ying, J., Srivastava, G., Hsieh, W., Gao, Z., Murray, P. G., Liao, S.-K., Ambinder, R. F., & Tao, Q. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0267 · Cited by 215 · see citing works

Epigenetic targets in hematopoietic malignancies

Claus, R., & Lübbert, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206814 · Cited by 214 · see citing works

Chromatin in Need of a Fix: Phosphorylation of H2AX Connects Chromatin to DNA Repair

Thiriet, C., & Hayes, J. J. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.05.008 · Cited by 205 · see citing works

γH2AX and its role in DNA double-strand break repairThis paper is one of a selection of papers published in this Special Issue, entitled 27th International West Coast Chromatin and Chromosome Conference, and has undergone the Journal's usual peer review process.

Fillingham, J., Keogh, M., & Krogan, N. J. (2006) · Biochemistry and Cell Biology · doi:10.1139/o06-072 · Cited by 190 · see citing works

DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia.

Garcia‐Manero, G., Daniel, J. J., Smith, T. L., Kornblau, S. M., Lee, M. S., Kantarjian, H. M., & Issa, J. J. (2002) · PubMed · Cited by 187 · see citing works

siRNA target site secondary structure predictions using local stable substructures

Heale, B. S. E. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni026 · Cited by 176 · see citing works

Histone Deacetylase (HDAC) Inhibitor LBH589 Increases Duration of γ-H2AX Foci and Confines HDAC4 to the Cytoplasm in Irradiated Non–Small Cell Lung Cancer

Geng, L., Cuneo, K. C., Fu, A., Tu, T., Atadja, P. W., & Hallahan, D. E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0049 · Cited by 163 · see citing works

Myc represses the growth arrest gene gadd45

Marhin, W. W., Chen, S., Facchini, L. M., Fornace, A. J., & Penn, L. Z. (1997) · Oncogene · doi:10.1038/sj.onc.1201138 · Cited by 152 · see citing works

Loss of Expression ofGADD45γ, a Growth Inhibitory Gene, in Human Pituitary Adenomas: Implications for Tumorigenesis

Zhang, X., Sun, H., Danila, D. C., Johnson, S. R., Zhou, Y., Swearingen, B., & Klibanski, A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8315 · Cited by 137 · see citing works

Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts

Bernhard, D., Ausserlechner, M., Tonko, M., Löffler, M., Hartmann, B., Csordas, A., & Kofler, R. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.14.1991 · Cited by 136 · see citing works

p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y

Hirose, T., Sowa, Y., Takahashi, S., Saito, S., Yasuda, C., Shindo, N., Furuichi, K., & Sakai, T. (2003) · Oncogene · doi:10.1038/sj.onc.1207091 · Cited by 128 · see citing works

BRCA1 Regulates GADD45 through Its Interactions with the OCT-1 and CAAT Motifs

Fan, W., Jin, S., Tong, T., Zhao, H., Fan, F., Antinore, M. J., Rajasekaran, B., Wu, M., & Zhan, Q. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110225200 · Cited by 125 · see citing works

Histone deacetylases as therapeutic targets in hematologic malignancies

Melnick, A. M., & Licht, J. D. (2002) · Current Opinion in Hematology · doi:10.1097/00062752-200207000-00010 · Cited by 117 · see citing works

Loss of expression of the growth inhibitory gene GADD45γ, in human pituitary adenomas, is associated with CpG island methylation

Bahar, A., Bicknell, J., Simpson, D. J. W., Clayton, R. N., & Farrell, W. E. (2003) · Oncogene · doi:10.1038/sj.onc.1207193 · Cited by 97 · see citing works

BRCA1 activation of the GADD45 promoter

Jin, S., Zhao, H., Fan, F., Blanck, P., Fan, W., Colchagie, A. B., Fornace, A. J., & Zhan, Q. (2000) · Oncogene · doi:10.1038/sj.onc.1203759 · Cited by 91 · see citing works

Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) α and β messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells

Chen, Z., Clark, S., Birkeland, M., Sung, C.-M., Lago, A., Liu, R., Kirkpatrick, R., Johanson, K., Winkler, J. D., & Hu, E. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00322-1 · Cited by 87 · see citing works

Myc suppresses induction of the growth arrest genes gadd34, gadd45, and gadd153 by DNA-damaging agents

Amundson, S. A., Zhan, Q., Penn, L. Z., & Fornace, A. J. (1998) · Oncogene · doi:10.1038/sj.onc.1202136 · Cited by 87 · see citing works

Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor

Sánchez‐González, B., Yang, H., Bueso-Ramos, C., Hoshino, K., Quintás‐Cardama, A., Richon, V. M., & Garcia‐Manero, G. (2006) · Blood · doi:10.1182/blood-2005-09-008086 · Cited by 80 · see citing works

DNA methylation patterns at relapse in adult acute lymphocytic leukemia.

Garcia‐Manero, G., Bueso-Ramos, C., Daniel, J. J., Williamson, J., Kantarjian, H. M., & Issa, J. J. (2002) · PubMed · Cited by 74 · see citing works

Salvage Therapy for Refractory or Relapsed Acute Lymphocytic Leukemia

Garcia‐Manero, G., & Thomas, D. A. (2001) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70204-5 · Cited by 72 · see citing works

The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines

Batova, A., Shao, L., Diccianni, M. B., Yu, A. L.-T., Rephaeli, A., Nudelman, A., & Yu, J. (2002) · Blood · doi:10.1182/blood-2002-02-0567 · Cited by 72 · see citing works

Survival of patients with high grade glioma treated with intrathecal thiotriethylenephosphoramide for ependymal or leptomeningeal gliomatosis

Witham, T. F., Fukui, M. B., MELTZER, C. C., Burns, R., Kondziolka, D. S., & Bozik, M. E. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991001)86:7 · Cited by 64 · see citing works

Clinical and biological importance of cytogenetic abnormalities in childhood and adult acute lymphoblastic leukemia

Johansson, B., Mertens, F., & Mitelman, F. (2004) · Annals of Medicine · doi:10.1080/07853890410018808 · Cited by 59 · see citing works

A Novel Pathway Involving Melanoma Differentiation Associated Gene-7/Interleukin-24 Mediates Nonsteroidal Anti-inflammatory Drug–Induced Apoptosis and Growth Arrest of Cancer Cells

Zerbini, L. F., Czibere, A. G., Wang, Y., Correa, R. G., Otu, H. H., Joseph, M. G., Takayasu, Y., Silver, M., Gu, X., Ruchusatsawat, K., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2068 · Cited by 59 · see citing works

Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia.

Romanski, A., Bacic, B., Bug, G., Pfeifer, H., Gül, H., Remiszewski, S., Hoelzer, D. F., Atadja, P. W., Ruthardt, M., & Ottmann, O. G. (2004) · PubMed · Cited by 59 · see citing works

Apoptotic Cytotoxic Effects of a Histone Deacetylase Inhibitor, FK228, on Malignant Lymphoid Cells

Murata, M., Towatari, M., Kosugi, H., Tanimoto, M., Ueda, R., Saito, H., & Naoe, T. (2000) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2000.tb00899.x · Cited by 40 · see citing works

GADD45γ, down-regulated in 65% Hepatocellular Carcinoma (HCC) from 23 Chinese patients, inhibits cell growth and induces cell cycle G2/M arrest for Hepatoma Hep-G2 cell lines

Sun, L., Gong, R., Wan, B., Huang, X., Wu, C., Zhang, X., Zhao, S., & Yu, L. (2003) · Molecular Biology Reports · doi:10.1023/a:1026370726763 · Cited by 38 · see citing works

IDA-FLAG Regimen for the Therapy of Primary Refractory and Relapse Acute Leukemia: A Single-Center Experience

Yavuz, S., Paydaş, S., Dişel, U., & Şahin, B. (2006) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000181690.21601.09 · Cited by 35 · see citing works

Rapid Assessment of Anti-HIV siRNA Efficacy Using PCR-Derived Pol III shRNA Cassettes

Scherer, L. J., Yildiz, Y., Kim, J., Cagnon, L., Heale, B. S. E., & Rossi, J. J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.003 · Cited by 31 · see citing works

Gadd45γ Expression Is Reduced in Anaplastic Thyroid Cancer and Its Reexpression Results in Apoptosis

Chung, H. K., Yi, Y. W., Jung, N., Kim, D., Suh, J. M., Kim, H., Park, K. C., Kim, D. W., Hwang, E. S., Song, J. H., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-022031 · Cited by 26 · see citing works

Histone deacetylase inhibitor BL1521 induces a G1‐phase arrest in neuroblastoma cells through altered expression of cell cycle proteins

Ouwehand, K., de Ruijter, A. J. M., van Bree, C., Caron, H. N., & Kuilenburg, A. B. P. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.01.058 · Cited by 25 · see citing works

Imatinib

Cross, S. A., & Lyseng-Williamson, K. A. (2007) · Drugs · doi:10.2165/00003495-200767170-00013 · Cited by 18 · see citing works

Gadd45γ is androgen-responsive and growth-inhibitory in prostate cancer cells

Jiang, F., & Wang, Z. (2003) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2003.10.050 · Cited by 15 · see citing works

Advances in acute lymphoblastic leukemia.

Randolph, T. R. (2004) · PubMed · Cited by 13 · see citing works

Proteomic analysis of MOLT-4 cells treated by valproic acid

Vávrová, J., Janovská, S., Řezáčová, M., Hernychová, L., Tichá, Z., Vokurková, D., Záškodová, D., & Lukášová, E. (2007) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-007-9455-0 · Cited by 7 · see citing works

Imatinib in Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia

Waßmann, B. (2007) · Drugs · doi:10.2165/00003495-200767170-00016 · Cited by 1 · see citing works

Aberrant Epigenetic Landscape in Cancer: How Cellular Identity Goes Awry

Berdasco, M., & Esteller, M. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.10.005 · Cited by 623 · see citing works

Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability

Lauffer, B. E. L., Mintzer, R., Fong, R., Mukund, S., Tam, C., Zilberleyb, I., Flicke, B., Ritscher, A., Fedorowicz, G., Vallero, R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.490706 · Cited by 429 · see citing works

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

Tan, J., Cang, S., Ma, Y., Petrillo, R. L., & Liu, D. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-5 · Cited by 425 · see citing works

Trials with ‘epigenetic’ drugs: An update

Nebbioso, A., Carafa, V., Benedetti, R., & Altucci, L. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.004 · Cited by 237 · see citing works

Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells

Rajendran, P., Ho, E., Williams, D. E., & Dashwood, R. H. (2011) · Clinical Epigenetics · doi:10.1186/1868-7083-3-4 · Cited by 219 · see citing works

Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

Kirschbaum, M. H., Frankel, P. H., Popplewell, L. L., Zain, J. M., Delioukina, M. L., Pullarkat, V. A., Matsuoka, D., Pulone, B., Rotter, A. J., Espinoza‐Delgado, I., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.1398 · Cited by 213 · see citing works

γH2AX and its role in DNA double-strand break repairThis paper is one of a selection of papers published in this Special Issue, entitled 27th International West Coast Chromatin and Chromosome Conference, and has undergone the Journal's usual peer review process.

Fillingham, J., Keogh, M., & Krogan, N. J. (2006) · Biochemistry and Cell Biology · doi:10.1139/o06-072 · Cited by 190 · see citing works

Painful Pathways Induced by TLR Stimulation of Dorsal Root Ganglion Neurons

Jia, Q., Buzás, K., Fan, H., Cohen, J. I., Wang, K., Mont, E. K., Klinman, D. M., Oppenheim, J. J., & Howard, O. M. Z. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1001241 · Cited by 168 · see citing works

Genetic syndromes caused by mutations in epigenetic genes

Berdasco, M., & Esteller, M. (2013) · Human Genetics · doi:10.1007/s00439-013-1271-x · Cited by 165 · see citing works

Targeting Histone Deacetylases for Cancer Therapy: From Molecular Mechanisms to Clinical Implications

Li, Z., & Zhu, W. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.9067 · Cited by 160 · see citing works

Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study

Molokie, R. E., Lavelle, D., Gowhari, M., Pacini, M., Krauz, L., Hassan, J., Ibañez, V., Ruiz, M. A., Ng, K. P., Woost, P. G., et al. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002382 · Cited by 147 · see citing works

CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells

Gong, K., Xie, J., Yi, H., & Li, W. (2012) · Biochemical Journal · doi:10.1042/bj20111685 · Cited by 130 · see citing works

STAT3 Inhibition Is a Therapeutic Strategy for ABC-like Diffuse Large B-Cell Lymphoma

Scuto, A., Kujawski, M., Kowolik, C. M., Krymskaya, L., Wang, L., Weiss, L. M., DiGiusto, D. L., Yu, H., Forman, S. J., & Jove, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2380 · Cited by 114 · see citing works

HDAC8 catalyzes the hydrolysis of long chain fatty acyl lysine

Aramsangtienchai, P., Spiegelman, N. A., He, B., Miller, S. P., Dai, L., Zhao, Y., & Lin, H. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00396 · Cited by 118 · see citing works

Targeting the acetylation signaling pathway in cancer therapy

Dang, F., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.001 · Cited by 109 · see citing works

Advances in Chemical Priming to Enhance Abiotic Stress Tolerance in Plants

Sako, K., Nguyen, H. M., & Seki, M. (2020) · Plant and Cell Physiology · doi:10.1093/pcp/pcaa119 · Cited by 106 · see citing works

Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels

Kretzner, L., Scuto, A., Dino, P. M., Kowolik, C. M., Wu, J., Ventura, P. B., Jove, R., Forman, S. J., Yen, Y., & Kirschbaum, M. H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2259 · Cited by 102 · see citing works

HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells

Song, W., Tai, Y.-T., Tian, Z., Hideshima, T., Chauhan, D., Nanjappa, P., Exley, M. A., Anderson, K. C., & Munshi, N. C. (2010) · Leukemia · doi:10.1038/leu.2010.244 · Cited by 96 · see citing works

PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1–Dependent Mechanisms In Vitro and In Vivo

Rahmani, M., Aust, M. M., Benson, E. C., Wallace, L. M., Friedberg, J. W., & Grant, S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0034 · Cited by 93 · see citing works

Stemness of B-cell Progenitors in Multiple Myeloma Bone Marrow

Boucher, K., Parquet, N., Widen, R. E., Shain, K. H., Baz, R., Alsina, M., Koomen, J. M., Anasetti, C., Dalton, W. S., & Perez, L. E. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0531 · Cited by 87 · see citing works

Large-scale RNAi screening uncovers therapeutic targets in the parasite Schistosoma mansoni

Wang, J., Paz, C., Padalino, G., Coghlan, A., Lu, Z., Grădinaru, I., Collins, J. N. R., Berriman, M., Hoffmann, K. F., & Collins, J. J. (2020) · Science · doi:10.1126/science.abb7699 · Cited by 85 · see citing works

Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL

Stubbs, M. C., Kim, W., Bariteau, M. A., Davis, T. N., Vempati, S., Minehart, J., Witkin, M., Qi, J., Krivtsov, A., Bradner, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1290 · Cited by 71 · see citing works

DAPK plays an important role in panobinostat-induced autophagy and commits cells to apoptosis under autophagy deficient conditions

Gandesiri, M., Chakilam, S., Ivanovska, J., Benderska, N., Ocker, M., Fazio, P. D., Feoktistova, M., Gali‐Muhtasib, H. U., Rave‐Fränk, M., Prante, O., et al. (2012) · APOPTOSIS · doi:10.1007/s10495-012-0757-7 · Cited by 80 · see citing works

A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517

Kirschbaum, M. H., Goldman, B. H., Zain, J. M., Cook, J. R., Rimsza, L. M., Forman, S. J., & Fisher, R. I. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.608448 · Cited by 73 · see citing works

Active DNA demethylation in post-mitotic neurons: A reason for optimism

Gavin, D. P., Chase, K. A., & Sharma, R. P. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.036 · Cited by 72 · see citing works

Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19

Li, X., Zhang, Z., Wang, Z., Gutiérrez-Castrellón, P., & Shi, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01043-6 · Cited by 67 · see citing works

Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide)

Xia, C., Leon-Ferre, R. A., Laux, D. E., Deutsch, J. M., Smith, B. J., Frees, M., & Milhem, M. M. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2501-1 · Cited by 66 · see citing works

Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors

Yuan, Z., Sun, Q., Li, D., Miao, S., Chen, S., Song, L., Gao, C., Chen, Y., Tan, C., & Jiang, Y. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.017 · Cited by 62 · see citing works

SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells

Scuto, A., Kirschbaum, M. H., Buettner, R., Kujawski, M., Cermak, J. M., Atadja, P. W., & Jove, R. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.159 · Cited by 61 · see citing works

Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia

Sanda, T., Li, X., Gutiérrez, A., Ahn, Y., Neuberg, D. S., O’Neil, J., Strack, P. R., Winter, C. G., Winter, S. S., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235143 · Cited by 60 · see citing works

Development of a versatile DNMT and HDAC inhibitor C02S modulating multiple cancer hallmarks for breast cancer therapy

Yuan, Z., Chen, S., Gao, C., Dai, Q., Zhang, C., Sun, Q., Lin, J., Guo, C., Chen, Y., & Jiang, Y. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.03.027 · Cited by 58 · see citing works

The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression

Chen, S., Ye, J., Kijima, I., & Evans, D. B. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000917107 · Cited by 58 · see citing works

Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat)

Kubo, M., Kanaya, N., Petrossian, K., Ye, J., Warden, C., Liu, Z., Nishimura, R., Osako, T., Okido, M., Shimada, K., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2332-x · Cited by 56 · see citing works

Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo

Catalano, M. G., Pugliese, M., Gargantini, E., Grange, C., Bussolati, B., Asioli, S., Bosco, O., Poli, R., Compagnone, A., Bandino, A., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26057 · Cited by 56 · see citing works

CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma

Ramkumar, P., Abarientos, A., Tian, R., Seyler, M., Leong, J. T., Chen, M., Choudhry, P., Hechler, T., Shah, N. D., Wong, S. W. K., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001346 · Cited by 54 · see citing works

The Role of HDACs in the Response of Cancer Cells to Cellular Stress and the Potential for Therapeutic Intervention

Alseksek, R. K., Ramadan, W. S. H., Saleh, E., & El‐Awady, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158141 · Cited by 59 · see citing works

Targeting c-FLICE-like inhibitory protein (CFLAR) in cancer

Fulda, S. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.736499 · Cited by 55 · see citing works

SOX7 regulates MAPK/ERK-BIM mediated apoptosis in cancer cells

Sun, Q., Ding, L., Johnson, K. J., Zhou, S., Tyner, J. W., Yang, H. H., Doan, N., SAID, J. W., Xiao, J., Loh, X.-Y., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0865-8 · Cited by 53 · see citing works

p53-Independent, Normal Stem Cell Sparing Epigenetic Differentiation Therapy for Myeloid and Other Malignancies

Saunthararajah, Y., Triozzi, P. L., Rini, B. I., Singh, A. D., Radivoyevitch, T., Sekeres, M. A., Advani, A. S., Tiu, R. V., Reu, F. J., Kalaycio, M. E., et al. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.11.011 · Cited by 53 · see citing works

HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity

Sharma, V., Koul, N., Joseph, C., Dixit, D., Ghosh, S., & Sen, E. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00844.x · Cited by 53 · see citing works

Fetal Hemoglobin Induction by Epigenetic Drugs

Lavelle, D., Engel, J. D., & Saunthararajah, Y. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.04.008 · Cited by 52 · see citing works

The role of death domain proteins in host response upon SARS-CoV-2 infection: modulation of programmed cell death and translational applications

Ivanisenko, N. V., Seyrek, K., Kolchanov, N. A., Иванисенко, В. А., & Lavrik, I. N. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-00331-w · Cited by 51 · see citing works

Epigenetic Targets and their Inhibitors in Cancer Therapy

Zhao, L., Duan, Y., Lü, P., Zhang, Z., Zheng, X., Wang, J., & Feng, W. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666181224095449 · Cited by 50 · see citing works

Gene silencing of MIR22 in acute lymphoblastic leukaemia involves histone modifications independent of promoter DNA methylation

Li, X., Liu, J., Zhou, R., Huang, S., Huang, S., & Chen, X. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07920.x · Cited by 46 · see citing works

Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia

Vilas‐Zornoza, A., Agirre, X., Abizanda, G., Moreno, C., Segura, V., Martino, A. D., José‐Eneriz, E. S., Miranda, E., Martín-Subero, J. I., Gárate, L., et al. (2012) · Leukemia · doi:10.1038/leu.2012.31 · Cited by 44 · see citing works

Epigenetics and Epi-miRNAs: Potential markers/therapeutics in leukemia

Memari, F., Joneidi, Z., Taheri, B., Aval, S. F., Roointan, A., & Zarghami, N. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.07.133 · Cited by 43 · see citing works

Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia

Zhang, C., Zhong, J. F., Stucky, A., Chen, X., Press, M. F., & Zhang, X. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0151-8 · Cited by 43 · see citing works

Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions

Zavras, P. D., Shastri, A., Goldfinger, M., Verma, A. K., & Saunthararajah, Y. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2139 · Cited by 41 · see citing works

Dysregulation of Aromatase in Breast, Endometrial, and Ovarian Cancers

Manna, P. R., Molehin, D., & Ahmed, A. U. (2016) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2016.10.002 · Cited by 40 · see citing works

Histone deacetylase inhibitors in lymphoma

Copeland, A. R. M., Buglio, D., & Younes, A. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833d5954 · Cited by 39 · see citing works

Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations

Korfi, K., Ali, S. E., Heward, J. A., & Fitzgibbon, J. (2017) · Epigenetics · doi:10.1080/15592294.2017.1282587 · Cited by 39 · see citing works

GADD45g acts as a novel tumor suppressor, and its activation suggests new combination regimens for the treatment of AML

Guo, D., Zhao, Y., Wang, N., You, N. Y., Zhu, W., Zhang, P., Ren, Q., Yin, J., Cheng, T., & Ma, X. (2021) · Blood · doi:10.1182/blood.2020008229 · Cited by 39 · see citing works

Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development

Lee‐Sherick, A. B., Linger, R. M. A., Gore, L., Keating, A. K., & Graham, D. K. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08282.x · Cited by 38 · see citing works

Panobinostat induces apoptosis via production of reactive oxygen species and synergizes with topoisomerase inhibitors in cervical cancer cells

Wasim, L., & Chopra, M. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.10.057 · Cited by 39 · see citing works

Panobinostat for the treatment of multiple myeloma

Neri, P. E., Bahlis, N. J., & Lonial, S. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.668883 · Cited by 37 · see citing works

Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo

Qi, W., Zhang, W., Edwards, H. J., Chu, R. L., Madlambayan, G. J., Taub, J. W., Wang, Z., Wang, Y., Li, C., Lin, H., et al. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1095406 · Cited by 36 · see citing works

Co-exposure to polycyclic aromatic hydrocarbons and metals, four common polymorphisms in microRNA genes, and their gene-environment interactions: Influences on oxidative damage levels in Chinese coke oven workers

Xie, Y., Lin, T., Yang, M., Zhang, Z., Deng, N., Tang, M., Xiao, Y., Guo, H., & Deng, Q. (2019) · Environment International · doi:10.1016/j.envint.2019.105055 · Cited by 37 · see citing works

Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer

Wang, G., Niu, X., Zhang, W., Caldwell, J. T., Edwards, H. J., Chen, W., Taub, J. W., Zhao, L., & Ge, Y. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.10.015 · Cited by 35 · see citing works

Design and Synthesis of Simplified Largazole Analogues as Isoform-Selective Human Lysine Deacetylase Inhibitors

Reddy, D. N., Ballante, F., Chuang, T., Pirolli, A., Marrocco, B., & Marshall, G. R. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01632 · Cited by 31 · see citing works

Linking epithelial-to-mesenchymal-transition and epigenetic modifications

Stadler, S. C., & Allis, C. D. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.06.007 · Cited by 31 · see citing works

Panobinostat penetrates the blood–brain barrier and achieves effective brain concentrations in a murine model

Homan, M. J., Franson, A. T., Ravi, K., Roberts, H. J., Pai, M. P., Liu, C., He, M., Matvekas, A., Koschmann, C. J., & Marini, B. L. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04313-2 · Cited by 30 · see citing works

An Overview of HDAC Inhibitors and their Synthetic Routes

Peng, X., Liao, G., Sun, P., Yu, Z., & Chen, J. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190227221507 · Cited by 28 · see citing works

Novel Histone Deacetylase Inhibitors and HIV-1 Latency-Reversing Agents Identified by Large-Scale Virtual Screening

Divsalar, D. N., Simoben, C. V., Schonhofer, C., Richard, K., Sippl, W., Ntie‐Kang, F., & Tietjen, I. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00905 · Cited by 28 · see citing works

The Role of HDACs Inhibitors in Childhood and Adolescence AcuteLeukemias

Masetti, R., Serravalle, S., Biagi, C., & Pession, A. (2011) · BioMed Research International · doi:10.1155/2011/148046 · Cited by 29 · see citing works

Cytomegalovirus induces apoptosis in acute leukemia cells as a virus-versus-leukemia function

Koldehoff, M., Lindemann, M., Opalka, B., Bauer, S., Ross, R. S., & Elmaagacli, A. H. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1032968 · Cited by 29 · see citing works

Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicity

Mehrpouri, M., Safaroghli‐Azar, A., Pourbagheri‐Sigaroodi, A., Momeny, M., & Bashash, D. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173050 · Cited by 29 · see citing works

Targeting sickle cell disease root-cause pathophysiology with small molecules

Saunthararajah, Y. (2019) · Haematologica · doi:10.3324/haematol.2018.207530 · Cited by 28 · see citing works

Emerging Promise Of Epigenetics And Dna Methylation For The Diagnosis And Management Of Women‘S Cancers

Jones, A., Lechner, M., Fourkala, E.-O., Kristeleit, R. S., & Widschwendter, M. (2010) · Epigenomics · doi:10.2217/epi.09.47 · Cited by 27 · see citing works

Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies

Fratta, E., Montico, B., Rizzo, A., Colizzi, F., Sigalotti, L., & Dolcetti, R. (2016) · Oncotarget · doi:10.18632/oncotarget.10033 · Cited by 26 · see citing works

Histone deacetylase inhibitors: A new perspective for the treatment of leukemia

Abujamra, A. L., dos Santos, M. P., Roesler, R., Schwartsmann, G., & Brunetto, A. L. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.08.021 · Cited by 26 · see citing works

Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma

Guo, H., Zeng, D., Zhang, H., Bell, T., Yao, J., Liu, Y., Huang, S., Li, C. J., Lorence, E., Zhou, S., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0550-3 · Cited by 26 · see citing works

A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies

Goldberg, J., Sulis, M. L., Bender, J. G., Jeha, S., Gardner, R. A., Pollard, J. A., Aquino, V., Laetsch, T. W., Winick, N. J., Fu, C., et al. (2020) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2020.1752869 · Cited by 26 · see citing works

Discovery of indole-piperazine derivatives as selective histone deacetylase 6 inhibitors with neurite outgrowth-promoting activities and neuroprotective activities

Liang, T., Xie, Z., Dang, B., Wang, J., Zhang, T., Luan, X., Lu, T., Cao, C., & Chen, X. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129148 · Cited by 25 · see citing works

HDAC inhibitors: Promising agents for leukemia treatment

Deng, Y., Qian, C., & He, J. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.09.023 · Cited by 25 · see citing works

Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells

Yan-Fang, T., Li, Z., Li-Xiao, X., Fang, F., Lu, J., Li, G., Lan, C., Wang, N., Du, X., Sun, L., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126566 · Cited by 25 · see citing works

Chemical application improves stress resilience in plants

Bashir, K., Todaka, D., Sako, K., Ueda, M., Aziz, F., & Seki, M. (2025) · Plant Molecular Biology · doi:10.1007/s11103-025-01566-w · Cited by 24 · see citing works

Chemotherapy with hybrid liposomes for acute lymphatic leukemia leading to apoptosis in vivo

Ichihara, H., Ueno, J., Umebayashi, M., Matsumoto, Y., & Ueoka, R. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.12.041 · Cited by 23 · see citing works

Paradoxical Role of AT-rich Interactive Domain 1A in Restraining Pancreatic Carcinogenesis

Ferri-Borgogno, S., Barui, S., McGee, A. M., Griffiths, T., Singh, P. K., Piett, C. G., Ghosh, B., Bhattacharyya, S., Singhi, A., Pradhan, K., et al. (2020) · Cancers · doi:10.3390/cancers12092695 · Cited by 22 · see citing works

Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology

Barone, S., Cassese, E., Alfano, A. I., Brindisi, M., & Summa, V. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02067 · Cited by 22 · see citing works

Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors

Reddy, D. R., Ballante, F., Zhou, N., & Marshall, G. R. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.032 · Cited by 22 · see citing works

Mutated in colorectal cancer (MCC) is a novel oncogene in B lymphocytes

Edwards, S. K. E., Baron, J. E., Moore, C. R., Liu, Y., Perlman, D. H., Hart, R. P., & Xie, P. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0056-6 · Cited by 22 · see citing works

Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia

Vey, N., Prébet, T., Thalamas, C., Charbonnier, A., Rey, J., Kloos, I., Liu, E., Luan, Y., Vezan, R. N., Graef, T. T., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1263843 · Cited by 22 · see citing works

Histone Modification of Colorectal Cancer by Natural Products

Geng, Z., Chen, M., Yu, Q., Guo, S., Chen, T., & Liu, D. (2023) · Pharmaceuticals · doi:10.3390/ph16081095 · Cited by 21 · see citing works

New Therapeutic Strategies in Acute Lymphoblastic Leukemia

Jeha, S. (2008) · Seminars in Hematology · doi:10.1053/j.seminhematol.2008.09.009 · Cited by 21 · see citing works

Ultimate Precision: Targeting Cancer but Not Normal Self-replication

Velcheti, V., Schrump, D. S., & Saunthararajah, Y. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_199753 · Cited by 20 · see citing works

Hyper-activation of WNT/β-catenin signaling pathway mediates anti-tumor effects of histone deacetylase inhibitors in acute T lymphoblastic leukemia

Shao, N., Zou, J., Li, J., Chen, F., Dai, J., 曲迅, Sun, X., Ma, D., & Ji, C. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.663085 · Cited by 20 · see citing works

Multiple mechanisms determine the sensitivity of human-induced pluripotent stem cells to the inducible caspase-9 safety switch

Yagyu, S., Hoyos, V., Bufalo, F. D., & Brenner, M. K. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.3 · Cited by 20 · see citing works

Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia

Martin, A., Morgan, E. R., & Hijiya, N. (2012) · Pediatric Drugs · doi:10.1007/bf03262418 · Cited by 19 · see citing works

Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia

Shirazi, P. T., Eadie, L. N., Page, E. C., Heatley, S. L., Bruning, J. B., & White, D. L. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.027 · Cited by 19 · see citing works

Epigenetic Regulation of Cell Signaling Pathways in Acute Lymphoblastic Leukemia

José‐Eneriz, E. S., Agirre, X., Rodríguez‐Otero, P., & Prósper, F. (2013) · Epigenomics · doi:10.2217/epi.13.56 · Cited by 19 · see citing works

Inhibition of Plk1 and Cyclin B1 Expression Results in Panobinostat-Induced G2 Delay and Mitotic Defects

Prystowsky, M. B., Feeney, K. M., Kawachi, N., Montagna, C., Willmott, M., Wasson, C. W., Antkowiak, M. K., Loudig, O. D., & Parish, J. L. (2013) · Scientific Reports · doi:10.1038/srep02640 · Cited by 18 · see citing works

Identification of histone deacetylase inhibitors with (arylidene)aminoxy scaffold active in uveal melanoma cell lines

Nencetti, S., Cuffaro, D., Nuti, E., Ciccone, L., Rossello, A., Fabbi, M., Ballante, F., Ortore, G., Carbotti, G., Campelli, F., et al. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1835883 · Cited by 18 · see citing works

Cracking a cancer code histone deacetylation in epigenetic: the implication from molecular dynamics simulations on efficacy assessment of histone deacetylase inhibitors

Dushanan, R., Weerasinghe, S., Dissanayake, D. P., & Senthilnithy, R. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1838328 · Cited by 17 · see citing works

Combined inhibition of HDAC and DNMT1 induces p85α/MEK-mediated cell cycle arrest by dual target inhibitor 208 in U937 cells

Ren, Y., Sun, Q., Yuan, Z., & Jiang, Y. (2019) · Chinese Chemical Letters · doi:10.1016/j.cclet.2019.03.029 · Cited by 17 · see citing works

Everolimus Shows Synergistic Antimyeloma Effects with Bortezomib via the AKT/mTOR Pathway

Li, J., Liu, Z., Li, Y., Jing, Q., Wang, H., Liu, H., Chen, J., Feng, J., Shao, Q., & Fu, R. (2019) · Journal of Investigative Medicine · doi:10.1136/jim-2018-000780 · Cited by 15 · see citing works

Panobinostat inhibits breast cancer progression via Vps34-mediated exosomal pathway

Wang, X., & Yin, X. (2022) · Human Cell · doi:10.1007/s13577-022-00812-3 · Cited by 16 · see citing works

Low-dose LBH589 increases the sensitivity of cisplatin to cisplatin-resistant ovarian cancer cells

Ma, Y.-Y., Lin, H., Moh, J.-S., Chen, K., Wang, I.-W., Ou, Y., You, Y., & Lung, C.-C. (2011) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2011.01.022 · Cited by 16 · see citing works

Targeting Epigenetics through Histone Deacetylase Inhibitors in Acute Lymphoblastic Leukemia

Mummery, A., Narendran, A., & Lee, K.-Y. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911796798922 · Cited by 16 · see citing works

Prostaglandin E2 induces growth inhibition, apoptosis and differentiation in T and B cell-derived acute lymphoblastic leukemia cell lines (CCRF-CEM and Nalm-6)

Fard, S. S., Jeddi‐Tehrani, M., & Ardekani, A. M. (2012) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2012.04.012 · Cited by 16 · see citing works

The cross-talk of autophagy and apoptosis in breast carcinoma: implications for novel therapies?

Seyrek, K., Wohlfromm, F., Espe, J., & Lavrik, I. N. (2022) · Biochemical Journal · doi:10.1042/bcj20210676 · Cited by 14 · see citing works

Novel HDAC inhibitor, LBH589, potently blocks growth of Ph-negative acute lymphoblastic leukemia (ALL) cells and induces expression of DNA damage response genes

Scuto, A., Kirschbaum, M. H., Juhasz, A. N., Kretzner, L., Forman, S. J., Yen, Y., & Jove, R. (2007) · Cancer Research

Preclinical Activity of LBH589 Alone or in Combination with Chemotherapy in a Xenogeneic Mouse Model of Human Acute Lymphoblastic Leukemia

Agirre, X., Vilas‐Zornoza, A., Abizanda, G., Moreno, C., Segura, V., Martino, A. D., José‐Eneriz, E. S., Miranda, E., Martín-Subero, J. I., Gárate, L., et al. (2011) · Blood · doi:10.1182/blood.v118.21.1520.1520 · Cited by 4 · see citing works

Novel SIRT1 Agonists, SRT501 and SRT2183, Induce Expression of DNA Repair Genes and Apoptosis of Ph− Acute Lymphoblastic Leukemia Cells Alone and in Combination with the HDAC Inhibitor LBH589..

Scuto, A., Kirschbaum, M. H., Cermak, J. M., Atadja, P. W., & Jove, R. (2009) · Blood · doi:10.1182/blood.v114.22.3083.3083

Effect of histone deacetylase inhibitor LBH589 on proliferation, apoptosis and drug resistance of acute myeloid leukemia cell line HL60/ADM

Jiang, X., Zhao, Q., Wang, Z., Ding, B., Huang, K., Ye, J., & Meng, F. (2014) · 白血病·淋巴瘤 · doi:10.3760/cma.j.issn.1009-9921.2014.04.003

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3

George, P., Bali, P., Annavarapu, S., Scuto, A., Fiskus, W. C., Guo, F., Sigua, C. A., Sondarva, G. V., Moscinski, L. C., Atadja, P. W., et al. (2004) · Blood · doi:10.1182/blood-2004-09-3413 · Cited by 327 · see citing works